Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pacira receives European Commission approval for EXPAREL » 07:31
11/18/20
11/18
07:31
11/18/20
07:31
PCRX

Pacira

$64.70 /

+0.35 (+0.54%)

Pacira BioSciences…

Pacira BioSciences announced that the European Commission has granted marketing authorization for EXPAREL as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults. The European Commission approval was based on the results of four pivotal Phase 3 studies that demonstrated improvements in pain reduction and opioid use. These studies include: Lower Extremity Nerve Block Study: This study assessed the safety and efficacy of EXPAREL as a femoral nerve block in patients undergoing total knee arthroplasty. Results demonstrated that EXPAREL resulted in a significant reduction in cumulative pain scores over 72 hours compared to placebo. A higher percentage of patients who received EXPAREL were pain-free, consumed fewer opioids and reported higher satisfaction with their pain control compared with placebo. Upper Extremity Nerve Block Study: This study assessed the safety and efficacy of EXPAREL as an interscalene brachial plexus nerve block in patients undergoing total shoulder arthroplasty or rotator cuff repair. Results demonstrated that EXPAREL significantly improved pain control and reduced opioid consumption through 48 hours compared with placebo and a standardized pain management protocol alone. Hard Tissue Infiltration Study: This study assessed the safety and efficacy of EXPAREL administered via infiltration in patients undergoing bunionectomy. Results demonstrated that EXPAREL significantly reduced pain and opioid consumption compared with placebo over the first 24 hours following surgery than patients administered placebo. Soft Tissue Infiltration Study: This study assessed the safety and efficacy of EXPAREL administered via infiltration in patients undergoing hemorrhoidectomy. Results demonstrated that EXPAREL significantly reduced pain compared to placebo at all time points, including a 30 percent reduction in the cumulative pain scores at 72 hours. Patients who received EXPAREL consumed significantly fewer opioids than patients administered placebo. The European Commission decision is applicable to all 27 European Union member states plus the United Kingdom, Iceland, Norway and Liechtenstein. Commercial planning is underway, with an anticipated launch in the second half of 2021. EXPAREL was initially approved in the United States for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Since its launch, EXPAREL has been used in over seven and a half million patients.

ShowHide Related Items >><<
PCRX Pacira
$64.70 /

+0.35 (+0.54%)

PCRX Pacira
$64.70 /

+0.35 (+0.54%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$64.70 /

+0.35 (+0.54%)

PCRX Pacira
$64.70 /

+0.35 (+0.54%)

Hot Stocks
Paulson & Co. buys Lear, cuts Tiffany in Q3 » 16:52
11/16/20
11/16
16:52
11/16/20
16:52
LEA

Lear

$140.81 /

+2.79 (+2.02%)

, ENDP

Endo

$5.03 /

+0.235 (+4.90%)

, GOLD

Barrick Gold

$25.85 /

-0.05 (-0.19%)

, TCO

Taubman Centers

$42.80 /

+3.3 (+8.35%)

, SSRM

SSR Mining

$19.21 /

-0.495 (-2.51%)

, THM

International Tower Hill Mines

$1.49 /

-0.01 (-0.67%)

, TIF

Tiffany

$131.50 /

+0.135 (+0.10%)

, TAK

Takeda Pharmaceutical

$17.26 /

-0.04 (-0.23%)

, QGEN

Qiagen

$46.27 /

-1.46 (-3.06%)

, PCRX

Pacira

$64.25 /

+0.59 (+0.93%)

, HZNP

Horizon Therapeutics

$70.85 /

-1.49 (-2.06%)

, BHC

Bausch Health

$19.92 /

+0.32 (+1.63%)

, GLD

SPDR Gold Shares

$177.10 /

-0.08 (-0.05%)

, NG

NovaGold

$10.99 /

+0.14 (+1.29%)

, BSIG

BrightSphere

$18.14 /

+0.45 (+2.54%)

John Paulson's…

John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of September 30, 2020. Paulson's two new buys in the quarter included Lear (LEA). The fund increased its stake in five holdings, including by size of previous position Endo (ENDP), Barrick Gold (GOLD), Taubman Centers (TCO), SSR Mining (SSRM), and International Tower Hill Mines (THM). Paulson reduced its stake in six holdings, including by size of previous position Tiffany (TIF), Takeda Pharmaceuticals (TAK), Qiagen (QGEN), Pacira Biosciences (PCRX), and Horizon Therapeutics (HZNP). The fund's top holdings as of September 30, 2020, in order of size, were Horizon Therapeutics, Bausch Health (BHC), SPDR Gold Shares (GLD), Novagold Resources (NG), and Brightsphere Investment Group (BSIG).

ShowHide Related Items >><<
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

PCRX Pacira
$64.25 /

+0.59 (+0.93%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

GLD SPDR Gold Shares
$177.10 /

-0.08 (-0.05%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 Morgan Stanley
Lear upgraded to Overweight from Equal Weight at Morgan Stanley
11/02/20 Benchmark
Lear price target raised to $162 from $130 at Benchmark
10/22/20 JPMorgan
Lear price target raised to $149 from $125 at JPMorgan
ENDP Endo
$5.03 /

+0.235 (+4.90%)

10/20/20 H.C. Wainwright
BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright
10/05/20 Piper Sandler
Piper reiterates Overweight on Endo after dermatologist survey
09/25/20 Raymond James
Endo deal could generate $50M-$75M in cash inflow, says Raymond James
07/27/20 Goldman Sachs
Endo initiated with a Sell at Goldman Sachs
GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

10/22/20 National Bank
Barrick Gold price target lowered to C$42 from C$44 at National Bank
09/17/20 Jefferies
Freeport 'not an acquisition target for now,' says Jefferies
09/11/20 National Bank
Barrick Gold price target raised to C$44 from C$42 at National Bank
08/12/20 Canaccord
Barrick Gold upgraded to Buy from Hold at Canaccord
TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

11/16/20 Mizuho
Simon Property price target raised to $74 from $66 at Mizuho
11/16/20 Piper Sandler
Taubman Centers upgraded to Neutral from Underweight at Piper Sandler
09/09/20 Deutsche Bank
Deutsche closes near-term sell idea on Taubman Centers
07/01/20 Goldman Sachs
Taubman Centers assumed with Not Rated at Goldman Sachs
SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

10/22/20 National Bank
SSR Mining price target lowered to C$45 from C$46 at National Bank
10/13/20 Scotiabank
SSR Mining price target raised to C$39.50 from C$36 at Scotiabank
09/21/20 Canaccord
Canaccord maintains Buy on SSR Mining following merger with Alacer Gold
09/17/20 National Bank
SSR Mining coverage resumed with an Outperform at National Bank
THM International Tower Hill Mines
$1.49 /

-0.01 (-0.67%)

10/05/20 B. Riley Securities
B. Riley starts International Tower Hill Mines with Buy, $5 price target
10/05/20 B. Riley Securities
International Tower Hill Mines initiated with a Buy at B. Riley Securities
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

10/28/20
LVMH, Tiffany near agreement on $131.50 per share price, WSJ reports
10/16/20 William Blair
Tiffany results strengthen legal standing against LVMH, says William Blair
09/10/20 Wells Fargo
Tiffany price target lowered to $120 from $135 at Wells Fargo
08/25/20 Oppenheimer
Opco 'turning more concerned' LVMH could reduce Tiffany buyout price
TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

11/04/20 Berenberg
Qiagen price target raised to EUR 52 from EUR 50 at Berenberg
10/06/20 BofA
Qiagen resumed with Buy at BofA
10/06/20 BofA
Qiagen upgraded to Buy from Neutral at BofA
10/05/20 Citi
Citi opens 'positive catalyst watch' on Qiagen ahead of Q3 results
PCRX Pacira
$64.25 /

+0.59 (+0.93%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

11/03/20 BMO Capital
Horizon Therapeutics price target raised to $110 from $105 at BMO Capital
11/03/20 Citi
Horizon Therapeutics price target raised to $116 from $112 at Citi
10/14/20 Stifel
Horizon expected to meet or exceed Q3, 2020 expectations, says Stifel
10/01/20 Stifel
Stifel halves Selecta Biosciences target to $2, sees 'no reason to buy here'
BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

11/05/20 Piper Sandler
Bausch Health price target lowered to $25 from $26 at Piper Sandler
10/26/20 Barclays
Bausch Health price target raised to $29 from $28 at Barclays
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 BofA
Bausch Health upgraded to Neutral from Underperform at BofA
GLD SPDR Gold Shares
$177.10 /

-0.08 (-0.05%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

07/29/20 BofA
BrightSphere upgraded to Neutral from Underperform at BofA
07/28/20 Keefe Bruyette
BrightSphere upgraded to Outperform from Market Perform at Keefe Bruyette
05/12/20 Morgan Stanley
BrightSphere upgraded to Equal Weight from Underweight at Morgan Stanley
04/08/20 Morgan Stanley
BrightSphere downgraded to Underweight at Morgan Stanley
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

PCRX Pacira
$64.25 /

+0.59 (+0.93%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

  • 07
    Aug
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

PCRX Pacira
$64.25 /

+0.59 (+0.93%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

GLD SPDR Gold Shares
$177.10 /

-0.08 (-0.05%)

Hot Stocks
Pacira reports preliminary October net product sales $41.7M » 08:02
11/11/20
11/11
08:02
11/11/20
08:02
PCRX

Pacira

$59.06 /

+1.65 (+2.87%)

Pacira BioSciences…

Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera degrees of $40.7M and $1M, respectively, for the month of October 2020. The company's 2020 product sales have been negatively impacted by the COVID-19 pandemic, which mandated postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020. In order to provide greater transparency, the company will continue to report monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19.

ShowHide Related Items >><<
PCRX Pacira
$59.06 /

+1.65 (+2.87%)

PCRX Pacira
$59.06 /

+1.65 (+2.87%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$59.06 /

+1.65 (+2.87%)

PCRX Pacira
$59.06 /

+1.65 (+2.87%)

Hot Stocks
PainReform's Geller sees post-operative pain market as 'huge,' 'mostly unserved' » 14:41
11/02/20
11/02
14:41
11/02/20
14:41
PRFX

PainReform

$4.55 /

-0.15 (-3.19%)

, PCRX

Pacira

$52.12 /

-0.18 (-0.34%)

PainReform (PRFX) is a…

PainReform (PRFX) is a clinical stage biopharma company developing a treatment for post-operative pain relief. In an exclusive interview with The Fly, PainReform's Chairman Ehud Geller discussed the market opportunity for PRF-110 in post-operative pain: "There are 75M surgical procedures done in the U.S. a year. Of these, 45M approximately are very relevant for post-surgical pain treatments. That market opportunity is mostly unsatisfied. Surgeons in most cases use a fast-acting local anesthetic, which works for about five to six hours. If they were placed it in the wound during surgery, by the time the patient wakes up, most of the effect of the anesthetic is already dissipating or it's gone. Therefore, there's a market both for patient comfort and also for reducing the need of 'rescue opioids.' In most cases, nurses and doctors provide opioids to the patients who complain about pain. It's not like 90% gets Advil and 10% gets opioids. It's probably close to the opposite. Therefore, post-surgical pain is one of the major contributors to the opioid pandemic. That is the market; it's a huge market. There's only one product in the market called Exparel [from Pacira (PCRX)] but it only caters to less than 2% or 3% of the market. If you look at their revenues, they are high but it's mostly because they charge $299 or $300 a vial. The government in recognition of the importance of reduction of 'rescue opioids' in post-surgical pain has actually came out with regulation that frees the reimbursement for post-surgical pain, provided it is not opioids and it is long acting. It's a huge market, it's mostly unserved and it's especially now encouraged to be satisfied by regulation." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
PRFX PainReform
$4.55 /

-0.15 (-3.19%)

PCRX Pacira
$52.12 /

-0.18 (-0.34%)

PRFX PainReform
$4.55 /

-0.15 (-3.19%)

10/30/20 Maxim
PainReform initiated with a Buy at Maxim
PCRX Pacira
$52.12 /

-0.18 (-0.34%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$52.12 /

-0.18 (-0.34%)

PRFX PainReform
$4.55 /

-0.15 (-3.19%)

PCRX Pacira
$52.12 /

-0.18 (-0.34%)

Over a month ago
Earnings
Pacira reports Q3 adj. EPS 68c, consensus 63c » 08:07
10/29/20
10/29
08:07
10/29/20
08:07
PCRX

Pacira

$52.00 /

-0.84 (-1.59%)

Reports Q3 revenue…

Reports Q3 revenue $117.5M, consensus $115.58M. "Throughout the third quarter, we continued to make meaningful progress in growing EXPAREL sales despite lingering challenges in the elective surgery market due to the COVID-19 pandemic. The ongoing transition from procedures in the inpatient setting to the 23-hour ambulatory surgical center setting has accelerated because of the pandemic and we expect this trend to continue. The recent opening of our state-of-the art Pacira Innovation and Training Facility in Tampa is expected to further drive the adoption of EXPAREL and iovera degrees by providing digital and educational tools that meet the needs of our physician customers, as they seek to improve patient care in a variety of surgical settings. Looking ahead, Pacira remains well-positioned as the leading provider of innovative non-opioid pain management solutions," said Dave Stack, chairman and chief executive officer of Pacira BioSciences.

ShowHide Related Items >><<
PCRX Pacira
$52.00 /

-0.84 (-1.59%)

PCRX Pacira
$52.00 /

-0.84 (-1.59%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$52.00 /

-0.84 (-1.59%)

PCRX Pacira
$52.00 /

-0.84 (-1.59%)

Hot Stocks
Pacira launches Pacira Innovation and Training Center of Tampa » 07:42
10/21/20
10/21
07:42
10/21/20
07:42
PCRX

Pacira

$52.96 /

-1.79 (-3.27%)

Pacira BioSciences…

Pacira BioSciences announced the grand opening of the Pacira Innovation and Training Center of Tampa. Designed to advance clinician understanding of the latest local, regional and field block approaches for managing pain, the PITT will provide an unparalleled training environment for healthcare providers working to reduce or eliminate patient exposure to opioids. The PITT is a fully adaptable environment constructed with guidance and input from leaders in the field of regional anesthesia, and is equipped with state-of-the-art technology and audio/visual capabilities to support a full range of educational events from didactic presentations to hands-on workshops. The PITT features several distinct training spaces including a simulation lab equipped with seven ultrasound scanning stations; a lecture hall featuring a 4.5-foot-tall by 24-foot-wide LCD video wall to support live, virtual and even global presentations; and a green-screen broadcast studio designed to livestream content with single or multiple hosts.

ShowHide Related Items >><<
PCRX Pacira
$52.96 /

-1.79 (-3.27%)

PCRX Pacira
$52.96 /

-1.79 (-3.27%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$52.96 /

-1.79 (-3.27%)

PCRX Pacira
$52.96 /

-1.79 (-3.27%)

Conference/Events
Jefferies healthcare analyst to hold analyst/industry conference call » 12:25
10/19/20
10/19
12:25
10/19/20
12:25
PCRX

Pacira

$55.53 /

-0.52 (-0.93%)

Healthcare Analyst…

Healthcare Analyst Steinberg discusses new Exparel growth opportunities on an Analyst/Industry conference call to be held on October 19 at 1 pm.

ShowHide Related Items >><<
PCRX Pacira
$55.53 /

-0.52 (-0.93%)

PCRX Pacira
$55.53 /

-0.52 (-0.93%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$55.53 /

-0.52 (-0.93%)

PCRX Pacira
$55.53 /

-0.52 (-0.93%)

Conference/Events
Jefferies healthcare analyst to hold analyst/industry conference call » 09:51
10/19/20
10/19
09:51
10/19/20
09:51
PCRX

Pacira

$56.05 /

+ (+0.00%)

Healthcare Analyst…

Healthcare Analyst Steinberg discusses new Exparel growth opportunities on an Analyst/Industry conference call to be held on October 19 at 1 pm.

ShowHide Related Items >><<
PCRX Pacira
$56.05 /

+ (+0.00%)

PCRX Pacira
$56.05 /

+ (+0.00%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$56.05 /

+ (+0.00%)

PCRX Pacira
$56.05 /

+ (+0.00%)

Earnings
Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M » 08:03
10/07/20
10/07
08:03
10/07/20
08:03
PCRX

Pacira

$59.09 /

-0.93 (-1.55%)

"We are very…

"We are very encouraged with our strong performance as revenue and claims data show EXPAREL weekly growth rates exceeding those of the elective surgery market due to its expanding role in shifting a variety of complex surgical procedures to the 23-hour stay environment and broadening utilization in non-elective procedures, such as cesarean sections, cardiothoracic and oncology surgeries. When the elective surgery market recovers to its normal pace, we expect EXPAREL revenue to experience further growth," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "Demand for training around nerve and field blocks continues to grow and we remain on track to launch our state-of-the-art Innovation and Training Center in Tampa later this month. This facility will advance interactive, hands-on instruction around best practice field block techniques while improving patient care and enabling patient migration to the 23-hour stay environment."

ShowHide Related Items >><<
PCRX Pacira
$59.09 /

-0.93 (-1.55%)

PCRX Pacira
$59.09 /

-0.93 (-1.55%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
PCRX Pacira
$59.09 /

-0.93 (-1.55%)

PCRX Pacira
$59.09 /

-0.93 (-1.55%)

Recommendations
Pacira price target raised to $75 from $69 at Jefferies » 08:41
09/30/20
09/30
08:41
09/30/20
08:41
PCRX

Pacira

$59.35 /

+0.07 (+0.12%)

Jefferies analyst David…

Jefferies analyst David Steinberg raised the firm's price target on Pacira to $75 from $69 and keeps a Buy rating on the shares after his two surveys of ambulatory surgery center administrators and physicians increased his confidence in the long-term outlook for Exparel. Factoring in the survey responses, he now has higher conviction in his peak sales estimate of $800M, fine-tuned his near-term forecast, and raised his outyear projections by 7.5%, noted Steinberg.

ShowHide Related Items >><<
PCRX Pacira
$59.35 /

+0.07 (+0.12%)

PCRX Pacira
$59.35 /

+0.07 (+0.12%)

09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
08/10/20 H.C. Wainwright
Pacira price target raised to $70 from $68 at H.C. Wainwright
PCRX Pacira
$59.35 /

+0.07 (+0.12%)

PCRX Pacira
$59.35 /

+0.07 (+0.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.